Scientists trace new Drug's path in dialysis patients
NCT ID NCT07284043
Summary
This early-stage study aims to understand how the body processes and eliminates a new experimental drug called MT1013. It will involve 6 adults with a specific bone and mineral disorder related to kidney failure who are on regular dialysis. The main goal is to track where the drug goes and how it leaves the body, which is a standard first step in drug development.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMODIALYSIS SUBJECTS WITH SECONDARY HYPERPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
RECRUITINGJinan, Shandong, 250014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.